[ET Net News Agency, 21 December 2021] Nomura lowered its target price for Beigene
(06160) to HK$176.97 from HK$214.05 and maintained its "neutral" rating.
The research house said it lifts revenue forecasts for 2022F and 2023F to USD1,560m and
USD2,184m, respectively, to factor in the Novartis upfront payment and the likely
additional payment. (RC)